-transparent.png){kind=logo}
This study evaluated the efficacy of fludarabine, a new adenine nucleoside analogue, in typical and variant forms of hairy cell leukemia (HCL). Two patients with HCL and one patient with a variant form of HCL (HCL-variant) with resistant or progressive disease with prior treatments were studied. Fludarabine (30 mg/m2) was administered intravenously over 30 minutes daily for 5 days every month. Two patients (one with HCL and one with HCL-variant) achieved partial responses; the third patient had a minor response. This is the first report of encouraging activity of fludarabine in typical and variant forms of HCL. Further experience with fludarabine in these disorders is indicated.
H M Kantarjian, and
J Schachner, and
M J Keating
May 1991,
American journal of hematology,
H M Kantarjian, and
J Schachner, and
M J Keating
March 2012,
Blood,
H M Kantarjian, and
J Schachner, and
M J Keating
October 2018,
JAMA,
H M Kantarjian, and
J Schachner, and
M J Keating
August 1982,
The New England journal of medicine,
H M Kantarjian, and
J Schachner, and
M J Keating
April 1979,
Onkologie,
H M Kantarjian, and
J Schachner, and
M J Keating
October 1990,
Deutsche medizinische Wochenschrift (1946),
H M Kantarjian, and
J Schachner, and
M J Keating
July 2004,
Nihon rinsho. Japanese journal of clinical medicine,
H M Kantarjian, and
J Schachner, and
M J Keating
February 1987,
Cancer,
H M Kantarjian, and
J Schachner, and
M J Keating
December 1984,
Seminars in oncology,
H M Kantarjian, and
J Schachner, and
M J Keating
December 1984,
Seminars in oncology,
